VeerHealth Care Limited has released a comprehensive investor presentation under Regulation 30, showcasing its US FDA certification achievement and strategic expansion plans. The company secured US FDA certification for Drug (OTC) products following a successful audit that concluded in June 2025, positioning itself among the few small-cap companies globally with FDA-cleared manufacturing facilities.

Company Background and Strategic Evolution

VeerHealth Care was originally incorporated on July 10, 1992, as Niyati Leasing Limited, focusing on investment and finance activities. The company underwent strategic transformation in 2013 when management decided to diversify into the pharmaceutical sector, subsequently changing its name to VeerHealth Care Limited. In 2020, the company expanded into cosmetic manufacturing and specializes in producing pure vegetarian toothpaste.

Manufacturing Infrastructure and Capacity

The company operates from a state-of-the-art manufacturing facility spanning 90,000 sq. ft. in Vapi, equipped with comprehensive production and packaging capabilities. The facility includes specialized equipment for various product categories.

Financial Performance and Projections

The company has demonstrated consistent growth trajectory with strong financial fundamentals. The latest financial results show improved operational performance.

Expansion Plans and Funding Strategy

VeerHealth Care has announced an ambitious ₹33 crore expansion project to enhance healthcare solutions, covering land acquisition, building construction, procurement of machinery, and infrastructure development. The company will fund this expansion through a rights issue.

Global Market Presence and Strategic Partnerships

The company has established a significant international footprint, exporting products to multiple countries across different continents through both direct and merchant exporter channels.

Export Markets Include:

• Africa: Kenya, Uganda, Tanzania, Burundi, Rwanda, Morocco, Angola, Sudan, Somalia, Sierra Leone, Liberia
• Middle East: UAE, Yemen
• Asia: Hong Kong
• Americas: Haiti, Utah, North Carolina
• Europe: UK

The company has recently onboarded a leading FMCG company that operates in domestic and international markets within the personal and household care segment. This company is part of a 125-year-old prominent business group, representing a significant strategic partnership for VeerHealth Care.

Backward Integration and Product Innovation

VeerHealth Care has launched VeerPlast as a backward integration initiative in 2025, manufacturing packaging and components for its oral and personal care product lines. This division includes blow molding and injection molding capabilities, along with brush tufting and trimming lines to support export operations.

The company has successfully pioneered in manufacturing Clear Gel Toothpaste and exported the same to one of the top institutional supplier companies in the United States under Private Label. The company's Ayuveer brand has successfully completed onboarding on Myntra and is available on various e-commerce platforms including Amazon, Nykaa, and Flipkart.

Financial Strength and Asset Base

The company maintains a low-debt structure with borrowings of only ₹5-7 crore and substantial asset base including land assets valued at approximately ₹20 crore and total assets including machinery worth approximately ₹35 crore. The US FDA certification enables VeerHealth Care to export Drug (OTC) products to the USA and unlock access to other international markets, aligning with its "Local to Global" vision.

Veerhealth Care Limited has announced remarkable unaudited financial results for the quarter and nine months ended December 31, 2025, demonstrating exceptional year-over-year growth across key financial metrics. The Board of Directors approved these results at their meeting held on February 14, 2026, pursuant to Regulation 30 and 33 of the SEBI Listing Regulations.

Outstanding Financial Performance

The company delivered impressive growth metrics for Q3FY26, showcasing strong operational performance:

Detailed Financial Breakdown

The quarterly performance shows strong fundamentals with revenue from operations at ₹725.79 lakhs and total expenses managed at ₹647.02 lakhs:

Strategic Business Developments

Veerhealth Care has achieved several significant milestones positioning it for international expansion. The company received USFDA clearance, enabling exports of Drug (OTC) products to the USA and unlocking access to other international markets. This positions the company among very few small-cap companies globally with USFDA plant clearance.

Key strategic initiatives include discussions with a major Russian group for oral care exports and expected entry into the Russian market soon. The company has also completed onboarding of Ayuver products on Myntra, expanding its e-commerce presence across Amazon and Flipkart platforms.

Manufacturing and Operational Excellence

The company has commenced production at its new facility with in-house plastic molding for packaging and backward integration. Additionally, Veerhealth Care received regulatory approval from Food and Drug Authority, Gujarat for manufacturing personal care products for a leading marketplace company.

Management Outlook and Future Guidance

Managing Director Bhavin Shah expressed confidence in the company's trajectory, stating expectations to maintain high growth rates delivered in Q3FY26. The company has provided ambitious forward guidance with expected total revenues of ₹45-50 crores in FY 2026-27 with PAT margins of 7-10%.

Looking ahead, Veerhealth Care expects to reach revenue of ₹100 crores with PAT of 10% within the next 24 months, supported by expanding international operations and strengthening domestic presence.